Maxcyte Share Discussion Threads

[macc1] 23/4/2020 10:26

VIDEO - Short update from CEO Doug Doerfler:

[rambutan2] 22/4/2020 03:29

Finals out yesterday:

[pvb] 01/4/2020 12:09

FAO rambutan2

Latest @MTH

[rambutan2] 31/3/2020 21:50

For the record:

GAITHERSBURG, MD, and SOUTH SAN FRANCISCO, CA, 24 March 2020 - MaxCyte, Inc., (LSE: MXCT), a global cell-based therapies and life sciences company, and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(TM)) therapies for cancer, today announced a clinical and commercial license agreement. Under the terms of the agreement, Allogene gains rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform to develop and advance its AlloCAR T(TM) candidates through to commercialization. In return, MaxCyte will receive undisclosed development, approval and commercial milestones in addition to other licensing fees. The first two Allogene investigational therapies intended to utilize this validated gene editing and advanced proprietary cell manufacturing technology are directed at CD19 and BCMA targets.

MaxCyte's ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics. Allogene intends to deploy the MaxCyte technology to effect the gene editing steps during the production process. The closed system and high efficiency make it an ideal addition for GMP operations.

"MaxCyte's ExPERT platform has become the industry standard in electroporation technology and allows us to increase efficiency and improve yield, which is a critical component to the value proposition of our AlloCAR T(TM) therapies," said Alison Moore, Ph.D., Chief Technical Officer of Allogene.

Doug Doerfler, President & CEO of MaxCyte, said: "We're honored to partner with Allogene to help unlock the full potential of its next-generation allogeneic CAR T therapies through utilization of our Flow Electroporation(R) technology and ExPERT(TM) platform."

[supernumerary] 23/1/2020 10:05

Maybe, but I can't see a single holdings statement for the whole of 2019 - a bit odd given they raised £10M at the start of the year (at 170p 'approximately 11.6 per cent. of the Existing Common Stock') - but does indicate a pretty solid shareholder base.

[nimbo1] 23/1/2020 09:32

Could jump again.

Just noticed rmmc trust appear to have sold their position looking at q4 factsheet. Could explain the weakness of q4 19

[supernumerary] 22/1/2020 14:55

The Trinity Delta note here:

Not updating share price value, currently at 341p, while accepting there's been great progress over the period. Don't want to be blind-sided by imminent news I guess.

[supernumerary] 22/1/2020 12:32

I hear Numis and PG both issued updates yesterday. If anyone here has a copy, a PM would be appreciated...

[nimbo1] 22/1/2020 06:32

If they do float it I hope they go for the nasdaq - anything with a sniff of this kind of potential is instantly worth $500 mil over there!

[supernumerary] 21/1/2020 16:30

Analyst presentation now available via Maxcyte website:

[nimbo1] 21/1/2020 13:06

decent volume coming through now.

[edwardt] 21/1/2020 12:27

wakey wakey - how long till £100m m/c?

[edwardt] 20/1/2020 17:24

tell hargreaves no w8 ben is needed. it is listed here. hq is in US - they need to update their systems. think how many retail punters this has stopped buying due to the hassle factor!

[nimbo1] 20/1/2020 15:53

I listened to the analyst call - there is a presentation on the website investors should look at which accompanies the trading update.

This company has the look of one which could be much more valuable - only downside I can see other than risk to science etc which I have no clue about is the funding risk for carma but they seem to have a decent plan.

hxxps://www.maxcyte.com/wp-content/uploads/2020/01/MaxCyte-Trading-Update-YE-2019_FINAL-200120-WEB.pdf

[hahmedk] 20/1/2020 14:58

Thanks for the info. Just filled in the form and now contemplating buying. Not much selling at all

[timbo003] 20/1/2020 11:58

>>>>hahmed

It is a US based company (inc) which is traded on AIM

I first bought in at the IPO, so no W8ben was required. I topped up for the first time in November last year but had to do so through an account where I had a current w8ben on file (I think they last 2 or 3 years once submitted).

Today's updata is very encouraging, I wonder if the long term plan is to spin the Carma division off into a separate US quoted company?

[hahmedk] 20/1/2020 11:14

Is this US stock.HL asking for W8ben form first

[nimbo1] 20/1/2020 08:14

surely the start of a sustained move higher - no one is looking that is all.

[edwardt] 20/1/2020 08:02

Not sure what this company has to do to catch a bid..

[davep4] 18/12/2019 12:22

Large trade today.

[nimbo1] 25/11/2019 21:50

Could well be would make a lot of sense! Also as far as we know no institutions have downsized?

[edwardt] 25/11/2019 14:27

not sure why this qualified for EIS when it floated? Odd that the UK govt gives a tax kicker for what is a US business? In my mind that is pure nuts. Anyway, it may well explain the sell off post 3 years of float?

[nimbo1] 21/11/2019 13:21

yes i own some puretech

[edwardt] 21/11/2019 12:21

interesting to see that vor appears to have switched supplier to maxcyte - that is how i read it anyway. i also own prtc which is interesting as they are at the cutting edge in their space.